Home/Pipeline/OPN-401

OPN-401

Recurrent Pregnancy Loss

Phase 2bActiveN/A

Key Facts

Indication
Recurrent Pregnancy Loss
Phase
Phase 2b
Status
Active
Company

About Organon (2)

Organon is a mission-driven global healthcare company established in 2021 as a spin-off from Merck & Co., with a dedicated focus on women's health. Its strategy is built on three core pillars: advancing a portfolio of women's health therapies, expanding access through biosimilars, and maximizing the value of a broad range of established medicines. The company has achieved immediate global scale, operating in over 140 markets, and is recognized for its strong corporate governance and commitment to addressing healthcare inequities.

View full company profile

Other Recurrent Pregnancy Loss Drugs

DrugCompanyPhase
Pregnancy Loss AnalysisYourgene HealthCommercial